NTRP NextTrip Inc

On February 17, 2017, upon the recommendation of the Nominating and Governance Committee of the board of directors (the “Board”) of Neurotrope, Inc. (the “Company”), the Board appointed Andrew D. Perlman as a member of the Board, effective immediately, to hold office until the next annual meeting of the stockholders of the Company, until his successor is duly elected and qualified, or until his resignation or removal. Effective February 17, 2017, Mr. Perlman was appointed to serve as a member of the Audit Committee of the Board. Consistent with the Company’s standard compensation arrangements for non-employee directors, Mr. Perlman will receive an option to purchase, at an exercise price equal to the price at which the Company’s common stock closes on February 17, 2017, as reported by the OTCQB, up to (i) 7,813 shares of the Company’s common stock for his service to the Company as a non-employee director and (ii) 1,563 shares of the Company’s common stock for his service to the Company as a committee member, each such grant to vest in equal daily installments over a five-year period beginning on the date of grant. The options are granted subject to stock option agreements to be entered into by and between the Company and Mr. Perlman evidencing the granting of the options, substantially in the form of the Company’s standard form of stock option. There are no arrangements or understandings between Mr. Perlman and any other person pursuant to which he was selected as a director. The Company is not aware of any transaction in which Mr. Perlman has an interest requiring disclosure under Item 404(a) of Regulation S-K.